FR10C0024I1 - - Google Patents
Info
- Publication number
- FR10C0024I1 FR10C0024I1 FR10C0024C FR10C0024I1 FR 10C0024 I1 FR10C0024 I1 FR 10C0024I1 FR 10C0024 C FR10C0024 C FR 10C0024C FR 10C0024 I1 FR10C0024 I1 FR 10C0024I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97200099 | 1997-01-15 | ||
| EP98200068A EP0853945B1 (en) | 1997-01-15 | 1998-01-13 | Liquid gonadotropin containing formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR10C0024I1 true FR10C0024I1 (enExample) | 2010-05-21 |
| FR10C0024I2 FR10C0024I2 (fr) | 2011-04-01 |
Family
ID=8227932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR10C0024C Active FR10C0024I2 (fr) | 1997-01-15 | 2010-04-16 | Formulations liquides contenant une gonadotropine |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5929028A (enExample) |
| EP (2) | EP0853945B1 (enExample) |
| JP (1) | JP4353549B2 (enExample) |
| KR (1) | KR100498531B1 (enExample) |
| CN (1) | CN1165341C (enExample) |
| AR (1) | AR011410A1 (enExample) |
| AT (1) | ATE237348T1 (enExample) |
| AU (1) | AU736339B2 (enExample) |
| BR (1) | BR9800323B1 (enExample) |
| CA (1) | CA2226803A1 (enExample) |
| CZ (1) | CZ297419B6 (enExample) |
| DE (2) | DE122010000011I1 (enExample) |
| DK (1) | DK0853945T3 (enExample) |
| ES (1) | ES2196474T3 (enExample) |
| FR (1) | FR10C0024I2 (enExample) |
| HU (1) | HU227154B1 (enExample) |
| ID (1) | ID19499A (enExample) |
| IL (1) | IL122732A0 (enExample) |
| LU (1) | LU91655I2 (enExample) |
| MX (1) | MX9800438A (enExample) |
| NO (3) | NO322509B1 (enExample) |
| NZ (1) | NZ329572A (enExample) |
| PL (1) | PL190103B1 (enExample) |
| PT (1) | PT853945E (enExample) |
| RU (1) | RU2203086C2 (enExample) |
| SA (1) | SA98181124B1 (enExample) |
| TR (1) | TR199800062A2 (enExample) |
| TW (1) | TW518235B (enExample) |
| ZA (1) | ZA9883B (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL346127A1 (en) * | 1998-07-23 | 2002-01-28 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
| US20030166525A1 (en) | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| JP2007204498A (ja) * | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| MXPA02000404A (es) * | 1999-07-12 | 2004-05-21 | Grandis Biotech Gmbh | Formulaciones de hormona de crecimiento. |
| EP1261622B1 (en) * | 2000-02-22 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | Purified recombinant hlh having a specific bioactivity and process for purification thereof |
| US7256184B2 (en) * | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
| AU2007200662A1 (en) * | 2001-08-30 | 2007-03-08 | Kirin-Amgen, Inc. | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| EP1346843A1 (en) * | 2002-03-22 | 2003-09-24 | Fuji Photo Film Co., Ltd. | Image forming method |
| CA2518268C (en) | 2003-03-04 | 2013-12-10 | Aspenbio, Inc. | Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone |
| PT1610822E (pt) * | 2003-04-02 | 2011-01-05 | Ares Trading Sa | Formulações farmacêuticas líquidas ou liofilizadas de fsh e/ou lh em conjunto com o surfactante não iónico poloxâmero 188 e um agente bacteriostático |
| CN100488566C (zh) * | 2003-04-02 | 2009-05-20 | 阿雷斯贸易股份有限公司 | Fsh和lh以及非离子表面活性剂的液体药物制剂 |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| PL1638595T3 (pl) | 2003-06-20 | 2013-06-28 | Ares Trading Sa | Liofilizowane formulacje FSH/LH |
| JP4412989B2 (ja) * | 2003-12-15 | 2010-02-10 | 株式会社日立製作所 | 複数の記憶システムを有するデータ処理システム |
| KR100587535B1 (ko) * | 2004-02-04 | 2006-06-08 | 충남대학교산학협력단 | 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터 |
| TWI369401B (en) * | 2005-07-05 | 2012-08-01 | Ares Trading Sa | Serum-free culture medium for the production of recombinant gonadotropins |
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| WO2007056851A1 (en) * | 2005-11-17 | 2007-05-24 | Mount Sinai Hospital | Compositions and methods for enhancing ovulation inducing agents |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8450269B2 (en) * | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| JPWO2008038817A1 (ja) * | 2006-09-25 | 2010-01-28 | 国立大学法人東京農工大学 | 超音波操作装置および微細管内検査システム |
| KR20080106636A (ko) * | 2007-06-04 | 2008-12-09 | 동아제약주식회사 | 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액 |
| CA2692165A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| PT2170942E (pt) | 2007-06-28 | 2013-10-22 | Biogenerix Ag | Clone celular produtor de fsh |
| RS52566B (sr) * | 2007-11-01 | 2013-04-30 | Merck Serono S.A. | Tečne formulacije lh |
| KR101573773B1 (ko) * | 2008-02-08 | 2015-12-02 | 바이오제너릭스 게엠베하 | Ｆｓｈ의 액체 포뮬레이션 |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| CN102309745B (zh) * | 2008-09-17 | 2013-05-08 | 上海天伟生物制药有限公司 | 一种卵泡刺激素冻干针剂 |
| CN101347613B (zh) * | 2008-09-17 | 2011-10-26 | 上海天伟生物制药有限公司 | 几乎不含亚基的糖蛋白的组合物及其制备方法 |
| US8329649B2 (en) | 2008-11-04 | 2012-12-11 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone and histidine |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2325194A1 (en) | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012127501A2 (en) * | 2011-03-11 | 2012-09-27 | Sanzyme Limited | Composition for improving endometrial thickness during ovarian stimulation |
| WO2012127500A2 (en) * | 2011-03-11 | 2012-09-27 | Sanzyme Limited | Composition for spermatogenesis |
| US9757469B2 (en) | 2011-03-31 | 2017-09-12 | Ferring B.V. | Pharmaceutical preparation |
| US8680086B2 (en) | 2011-04-15 | 2014-03-25 | Neuralight Hd, Llc | Methods for chronic pain management and treatment using HCG |
| US20120265129A1 (en) | 2011-04-15 | 2012-10-18 | Neuralight Hd, Llc | Methods for Chronic Pain Management and Treatment using HCG |
| US9353172B2 (en) | 2011-07-18 | 2016-05-31 | Arts Biologics A/S | Long acting biologically active luteinizing hormone (LH) compound |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| WO2014063071A1 (en) | 2012-10-18 | 2014-04-24 | Neuralight Hd, Llc | Treatment of depression and ptsd |
| EA033788B1 (ru) | 2012-11-20 | 2019-11-26 | Opko Biologics Ltd | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина |
| JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2015075743A1 (en) | 2013-11-12 | 2015-05-28 | Cadila Healthcare Limited | Formulation for gonadotropins |
| SMT202100558T1 (it) * | 2014-10-21 | 2021-11-12 | Hexima Ltd | Un metodo di trattamento di infezioni fungine |
| CN107438623B (zh) | 2014-12-10 | 2023-07-14 | Opko生物科学有限公司 | 长效的ctp修饰的生长激素多肽的制备方法 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| HUE055449T2 (hu) | 2015-06-19 | 2021-11-29 | Opko Biologics Ltd | Hosszú hatástartamú koagulációs faktorok és eljárások ezek elõállítására |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| TW202444744A (zh) | 2016-07-11 | 2024-11-16 | 以色列商歐科生物製品有限公司 | 長效型凝血因子及其生產方法 |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
| CA3140267A1 (en) | 2019-05-16 | 2020-11-19 | Ceva Sante Animale | Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone |
| CN114404575A (zh) * | 2020-12-07 | 2022-04-29 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
| CN117783545A (zh) * | 2023-12-28 | 2024-03-29 | 深圳市新产业生物医学工程股份有限公司 | 经封闭剂封闭的软质材料、容器、液态校准品及检测试剂盒 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4357934A (en) * | 1980-07-23 | 1982-11-09 | The Curators Of The University Of Missouri | Method of treating male infertility |
| US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| IT1206302B (it) * | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5338835A (en) * | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
| ATE148171T1 (de) * | 1989-02-21 | 1997-02-15 | Univ Washington | Modifizierte formen von fortpflanzungshormonen |
| US5114948A (en) * | 1989-10-19 | 1992-05-19 | Eli Lilly And Company | Stabilized pergolide compositions |
| IE64738B1 (en) * | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| US5384132A (en) * | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
| US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| CA2133205C (en) * | 1992-04-30 | 2007-04-17 | Robert L. Swift | Stable polypeptide composition |
| US5281198A (en) * | 1992-05-04 | 1994-01-25 | Habley Medical Technology Corporation | Pharmaceutical component-mixing delivery assembly |
| RU2062619C1 (ru) * | 1994-02-08 | 1996-06-27 | Курский сельскохозяйственный институт им.проф.И.И.Иванова | Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных |
| WO1996029095A1 (en) * | 1995-03-21 | 1996-09-26 | Applied Research Systems Ars Holding N.V. | Hcg liquid formulations |
-
1997
- 1997-12-23 TW TW086119598A patent/TW518235B/zh not_active IP Right Cessation
- 1997-12-23 IL IL12273297A patent/IL122732A0/xx not_active IP Right Cessation
-
1998
- 1998-01-06 ZA ZA9883A patent/ZA9883B/xx unknown
- 1998-01-12 ID IDP980030A patent/ID19499A/id unknown
- 1998-01-13 EP EP98200068A patent/EP0853945B1/en not_active Expired - Lifetime
- 1998-01-13 CN CNB981041493A patent/CN1165341C/zh not_active Expired - Lifetime
- 1998-01-13 DE DE122010000011C patent/DE122010000011I1/de active Pending
- 1998-01-13 ES ES98200068T patent/ES2196474T3/es not_active Expired - Lifetime
- 1998-01-13 NZ NZ329572A patent/NZ329572A/xx not_active IP Right Cessation
- 1998-01-13 PT PT98200068T patent/PT853945E/pt unknown
- 1998-01-13 EP EP02079923A patent/EP1285665A1/en not_active Withdrawn
- 1998-01-13 AT AT98200068T patent/ATE237348T1/de active
- 1998-01-13 DE DE69813322T patent/DE69813322T2/de not_active Expired - Lifetime
- 1998-01-13 DK DK98200068T patent/DK0853945T3/da active
- 1998-01-14 CA CA002226803A patent/CA2226803A1/en not_active Abandoned
- 1998-01-14 AU AU52059/98A patent/AU736339B2/en not_active Expired
- 1998-01-14 RU RU98100930/14A patent/RU2203086C2/ru active Protection Beyond IP Right Term
- 1998-01-14 BR BRPI9800323-2A patent/BR9800323B1/pt not_active IP Right Cessation
- 1998-01-14 NO NO19980177A patent/NO322509B1/no not_active IP Right Cessation
- 1998-01-14 HU HU9800056A patent/HU227154B1/hu active Protection Beyond IP Right Term
- 1998-01-14 MX MX9800438A patent/MX9800438A/es active IP Right Grant
- 1998-01-14 PL PL98324279A patent/PL190103B1/pl unknown
- 1998-01-14 AR ARP980100152A patent/AR011410A1/es active IP Right Grant
- 1998-01-14 KR KR10-1998-0000785A patent/KR100498531B1/ko not_active Expired - Lifetime
- 1998-01-14 JP JP00538998A patent/JP4353549B2/ja not_active Expired - Lifetime
- 1998-01-15 CZ CZ0013598A patent/CZ297419B6/cs not_active IP Right Cessation
- 1998-01-15 TR TR1998/00062A patent/TR199800062A2/xx unknown
- 1998-04-14 US US09/006,812 patent/US5929028A/en not_active Expired - Lifetime
- 1998-04-22 SA SA98181124A patent/SA98181124B1/ar unknown
-
2010
- 2010-02-24 LU LU91655C patent/LU91655I2/fr unknown
- 2010-04-16 FR FR10C0024C patent/FR10C0024I2/fr active Active
- 2010-06-07 NO NO2010013C patent/NO2010013I2/no not_active IP Right Cessation
-
2021
- 2021-01-12 NO NO2021001C patent/NO2021001I1/no unknown